News | October 17, 2007

Cordis to Present Data Supporting Cypher at TCT 2007

October 18, 2007 - Cordis Corp. will present clinical data backing the CYPHER Sirolimus-eluting coronary stent at the annual Transcatheter Cardiovascular Therapeutics 2007 meeting (TCT 2007), which will take place in Washington, D.C. from October 20-25. Data from several studies will highlight the CYPHER Sirolimus-eluting Coronary Stent, as well as other products from the company’s peripheral vascular group.

“The studies that will be presented at this year's meeting will continue to add to the significant body of scientific evidence for the CYPHER Stent and our diverse portfolio of current and future products, which range from a carotid artery stent system to a wound closure device," said David E. Kandzari, M.D., F.A.C.C., F.S.C.A.I., Chief Medical Officer, Cordis Corporation. "The studies and presentations will further validate the clinical advantages of drug-eluting stents compared with bare metal stents, highlight economic data of stenting versus surgery, and feature the clinical benefits of the CYPHER Stent versus the Taxus Stent."

The schedule of key Cordis-related events includes:

SATURDAY, OCTOBER 20

3:15 p.m. Eastern Time (ET)

Carotid Workshop - Pooled Analysis of Three Carotid Artery Stenting Trials

Room 202A

Barry T. Katzen, M.D. of the Baptist Cardiac and Vascular Institute in Miami, Florida will present a pooled analysis of three carotid artery stenting trials to assess 30-day major adverse events rates, comprising death, all stroke and/or heart attack (myocardial infarction), in high-risk patients based on anatomic versus physiological risk factors. The analysis was pooled from the pivotal SAPPHIRE randomized and registry stent cohorts and the CASES-PMS study, which involved the PRECISE Stent and ANGIOGUARD Emboli Capture Guidewire.

No previous analysis has been reported regarding whether patients undergoing carotid artery stenting with emboli protection, who are at high-risk for carotid endarterectomy, have a higher risk for major adverse events based on anatomic versus co-existing physiological risk factors prior to carotid stenting. Additional analysis assessing one-year outcomes of these subgroups will also be presented.

3:32 p.m. ET

Oral Presentation - ECLIPSE Trial

Room 202B

S. Chiu Wong, M.D. of New York-Presbyterian Hospital/Weill Cornell Medical Center will present perspectives on extravascular sealing devices and a first report of the ECLIPSE Trial, a multicenter, non-blinded, randomized study designed to measure the safety and efficacy of the EXOSEAL(TM) Vascular Closure Device versus manual compression to close vascular access sites in patients having undergone diagnostic or interventional procedures.

The EXOSEAL(TM) Vascular Closure Device features a synthetic bioabsorbable polymer and is being studied to determine whether it can enable expedited hemostasis (the cessation of bleeding), faster patient ambulation (ability to walk) and reduced bed-stay after a catheterization procedure. Nearly eight million patients undergo cardiac catheterization procedures annually.

SUNDAY, OCTOBER 21

12:51 p.m. ET

Oral Presentation - ACROSS and PRISON II Trials

Ballroom C, Level 3

Dr. Kandzari will present six-month data results of the ACROSS Registry and PRISON II randomized clinical trial designed to evaluate the CYPHER Stent used in patients with chronic total occlusions.

MONDAY, OCTOBER 22

7:00 p.m. ET

Symposium - "New Evidence in DES Outcomes: The Road Traveled Since the World Congress of cardiology 2006"

Grand Hyatt Constitution Ballroom

A panel of distinguished speakers that includes Christian M. Spaulding, M.D., PhD of Cochin Hospital in France; Stephan Windecker, M.D. of Swiss Cardiovascular Center Bern in Switzerland; Jeffrey W. Moses, M.D., of Columbia University Medical Center in New York; and Lowell F. Satler, M.D. of Washington Hospital Center will discuss the drug-eluting stent landscape and how to apply current evidence to clinical practice. Topics of discussion will include the impact of media headlines on clinical practice, the latest data set on percutaneous coronary interventions, applying the evidence of drug-eluting stents to clinical practice and the future of sirolimus-eluting stents.

TUESDAY, OCTOBER 23

9:09 a.m. Eastern Time

Oral Presentation - "Temporal Trends in Coronary Revascularization Procedures, Outcomes and Costs: Results From the U.S. Medicare Program"

Room 151AB

Jason W. Ryan, M.D., M.P.H. of Beth Israel Deaconess Medical Center in Boston, Massachusetts will present a comparison of pre-drug-eluting stent implantation in 2001 to post-drug-eluting stent implantation in 2004; Dr. Ryan will provide an update on temporal trends, outcomes and costs from this time period associated with coronary revascularization procedures, including percutaneous interventions and bypass surgery, from the Medicare program in the United States.

WEDNESDAY, OCTOBER 24

1:45 p.m. ET

Oral Presentation - ARTS II

Coronary Theatre - Lower Level

Bernard De Bruyne, M.D., Ph.D. of Cardiovascular Center, OLV Hospital, Aalst, Belgium will present two-year data results from the ARTS-II Trial, which compared the safety and efficacy of the CYPHER Stent versus BMS and CABG. Dr. Bruyne will present data from the study assessing the impact of gender following multivessel drug-eluting stent implantation.

Source: www.cordis.com

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies| August 03, 2017
Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use of...
Onyx DES 2.0 mm stent meets primary endpoints in small vessels
News | June 12, 2017
June 12, 2017 – The Medtronic Resolute Onyx Drug-Eluting Stent (DES) met its primary endpoint of target lesion failur
First Pennsylvania Patient Treated in LEADERS FREE II Trial of BioFreedom Drug-Coated Stent
News | Stents Drug Eluting| May 12, 2017
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a trial assessing the safety and...
Resolute Onyx DES, drug eluting stent, medtronic, gains FDA approval
Technology | Stents Drug Eluting| May 01, 2017
May 1, 2017 — The U.S.
Sponsored Content | Videos | Stents Drug Eluting| May 01, 2017
This video, provided by Medtronic, demonstrates the Resolute Onyx coronary stent.
Biosensors, BioFreedom drug-coated stent, LEADERS FREE II IDE trial, first patient, U.S. pivotal study
News | Stents Drug Eluting| March 03, 2017
Biosensors International Group Ltd. announced in February enrollment of the first patient in LEADERS FREE II, its new...
CeloNova Cobra Pzf stent
Technology | Stents| March 02, 2017
March 2, 2017 — The U.S. Food and Drug Administration (FDA) cleared CeloNova BioSciences Inc.
Synergy stent, abluminal polymer DES, bioresorbable polymer DES, bioresorbable polymer metallic stent

The Synergy stent is the first FDA cleared drug-eluting stent to use a bioresorbable polymer drug carrier. When the polymer dissolves after about four months, the devices become a bare metal stent. The technology is supposed to reduce the rate of late stent thrombosis due to vessel inflammation caused by durable polymers.

Feature | Stents Bioresorbable| January 17, 2017 | Dave Fornell
One of the big advancements in drug-eluting stent (DES) technology has been the development of bioresorbable polymers
OCT, intravascular imaging, stent, good stent apposition on vessel wall, TRANSFORM-OCT study

An OCT image showing good stent strut apposition against the vessel wall.

News | Stents| January 13, 2017
January 13, 2017 — Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OC
Overlay Init